Bank of New York Mellon Corp Raises Stock Position in Emergent Biosolutions Inc. (NYSE:EBS)

Bank of New York Mellon Corp grew its position in Emergent Biosolutions Inc. (NYSE:EBS) by 40.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,003 shares of the biopharmaceutical company’s stock after buying an additional 4,894 shares during the period. Bank of New York Mellon Corp’s holdings in Emergent Biosolutions were worth $83,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in EBS. Covestor Ltd raised its holdings in Emergent Biosolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 2,893 shares during the period. EP Wealth Advisors LLC acquired a new stake in shares of Emergent Biosolutions during the fourth quarter valued at about $110,000. Alpine Global Management LLC acquired a new stake in shares of Emergent Biosolutions during the fourth quarter valued at about $112,000. Balyasny Asset Management L.P. purchased a new stake in shares of Emergent Biosolutions in the 4th quarter valued at approximately $127,000. Finally, HBK Sorce Advisory LLC acquired a new position in shares of Emergent Biosolutions in the 1st quarter worth approximately $131,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Insider Transactions at Emergent Biosolutions

In related news, Director Keith Katkin sold 7,844 shares of the business’s stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total transaction of $49,417.20. Following the completion of the transaction, the director directly owned 86,431 shares of the company’s stock, valued at $544,515.30. The trade was a 8.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.20% of the company’s stock.

Emergent Biosolutions Stock Down 0.7%

Shares of EBS opened at $6.06 on Thursday. The company’s 50-day simple moving average is $6.64 and its 200-day simple moving average is $6.70. The company has a debt-to-equity ratio of 1.20, a quick ratio of 3.51 and a current ratio of 6.32. Emergent Biosolutions Inc. has a 1 year low of $4.02 and a 1 year high of $13.28. The stock has a market capitalization of $328.72 million, a PE ratio of -2.23 and a beta of 1.97.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.42. Emergent Biosolutions had a negative net margin of 13.63% and a negative return on equity of 0.52%. The firm had revenue of $140.90 million for the quarter, compared to the consensus estimate of $148.55 million. Analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.